Sign In
Buy LCTX
$1.20
-0.0100 (-0.83%)
At Close: Jun 03, 2026
Lineage Cell Therapeutics to Present Tomorrow at 2020 Raymond James Human Health Innovation Conference
12:00am, Wednesday, 17'th Jun 2020
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medic
Atreca (BCEL) Receives a Rating Update from a Top Analyst - Markets
10:14am, Tuesday, 16'th Jun 2020
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Atreca (BCEL – Research Report),
H.C. Wainwright Reaffirms Their Hold Rating on PDS Biotechnology (PDSB) - Markets
03:47pm, Monday, 15'th Jun 2020
H.C. Wainwright analyst Joseph Pantginis maintained a Hold rating on PDS Biotechnology (PDSB – Research Report) today. The company’s shares
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Global Blood Therapeutics (GBT –
H.C. Wainwright Thinks Onconova Therapeutics' Stock is Going to Recover - Markets
10:18am, Monday, 15'th Jun 2020
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Onconova Therapeutics (ONTX – Research
Quick high-intensity workouts good for people with spinal cord injuries
10:01am, Monday, 15'th Jun 2020
Researchers have shed light on the practical advantages of high-intensity interval training (HIIT) or short bursts of all-out exercise for people who have experienced spinal cord injuries (SCI).
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts - ResearchAndMarkets.com
12:00am, Monday, 15'th Jun 2020
The
Lineage Cell Therapeutics to Present at 2020 Raymond James Human Health Innovation Conference on June 18, 2020
12:00pm, Thursday, 11'th Jun 2020
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Ch
Brokerages Anticipate Lineage Cell Therapeutics, Inc. (NASDAQ:LCTX) to Post ($0.04) Earnings Per Share
06:14am, Wednesday, 10'th Jun 2020
Shares of Lineage Cell Therapeutics, Inc. (NASDAQ:LCTX) have been given a consensus broker rating score of 1.40 (Strong Buy) from the five brokers that provide coverage for the company, Zacks Investme
Global COVID-19 Pipelines - Cell Therapies, Diagnostics, Treatments and Vaccines - ResearchAndMarkets.com
12:00am, Tuesday, 09'th Jun 2020
The
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage cell therapy company which manufactures and transplants specific cell types to treat diseases and serious medical condi
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage cell therapy company which manufactures and transplants specific cell types to treat diseases and serious medical condi
Lineage Cell Therapeutics to Participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020
12:00pm, Tuesday, 19'th May 2020
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that Brian M. Culley, Ch
AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
12:00am, Thursday, 14'th May 2020
AgeX Therapeutics , Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported fina
Lineage Cell Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
08:05pm, Thursday, 07'th May 2020
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today reported financial and operating r
